EventsThe 3rd International Electronic Conference on Biomolecules
Published
This submission belongs to the session 6. Bioinformatics and Computational Biology of the event The 3rd International Electronic Conference on Biomolecules
Published date
12 Apr, 2024
Academic Editor
author-avatarThomas Caulfield
Citation
Obinna Kenneth Didigwu, Emmanuel Amuchechukwu Kevin, Michael Osita Edeh, Sunday N. Okafor, In Silico Prediction of Drug-likeness, Pharmacokinetics, and Toxicity of Selected Phytotoxic Pyrrolizidine Alkaloids, in Proceedings of The 3rd International Electronic Conference on Biomolecules, 23 April–25 April 2024, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

In Silico Prediction of Drug-likeness, Pharmacokinetics, and Toxicity of Selected Phytotoxic Pyrrolizidine Alkaloids

1. Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, 410001 Enugu, Nigeria, Nigeria
2. Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria Nsukka, 410001 Enugu State, Nigeria, Nigeria
Abstract

Pyrrolizidine alkaloids (PAs) are heterocyclic organic compounds of natural origin synthesized by either plants or microorganisms. They are found in species applied in the pharmaceutical industry for their beneficial biological activities to cure disease; thus, a thorough knowledge of their pharmacokinetics and toxicity is of great importance as they are notorious for their acute hepatotoxicity and carcinogenicity in humans and animals. Therefore, this study evaluated the drug-likeness of 15 phytotoxic pyrrolizidine alkaloids that were reportedly isolated from 11 plant species via in silico prediction of their pharmacokinetic and toxicity profiles. Using Swiss ADME, pkCSM, and PreADMET webserver tools, Lipinski's properties and topological polar surface area (TPSA) were predicted for drug-likeness, alongside their pharmacokinetic profiles and toxicity on various organ endpoints. The drug-likeness prediction showed that all the compounds obeyed Lipinski’s rule of five (LRo5). None of the compounds inhibited hERG I and hERG II, indicating their non-cardiotoxic nature. In addition, 20% of the compounds elicited AMES toxicity; 53.33% caused liver injury; and none was sensitive to the skin. Furthermore, 13.33% showed high Caco-2 permeability and all displayed good skin permeability, implying their suitability for transdermal drug delivery. Moreover, P-glycoprotein was effluxed by 80% of the compounds and none exhibited inhibition; 86.66% of the compounds readily crossed the blood–brain barrier, 6.66% penetrated the central nervous system, none was a substrate to cytochrome p450 isoenzymes, 6.66% inhibited cytochrome p450 isoenzymes, 53.33% and 26.66% would cause cancer in mice and rats, respectively, and 20% showed high tolerated doses in humans. All demonstrated high intestinal absorption and 46.66% demonstrated good water solubility while a significant number showed a moderate volume of distribution, were free-flowing in plasma, and demonstrated moderate bioavailability. This study identified Jacoline and monocrotaline as drug-like, non-toxic, and highly bioavailable pyrrolizidine alkaloids with strong potential for further assessment, optimization, and development.

Keywords
pyrrolidine alkaloids
drug-likeness
pharmacokinetic profiles
toxicity
in silico.
High Endomucin Expression Correlates with a Favorable Immune Landscape and Improved Survival in Clear-Cell Renal Cell Carcinoma (ccRCC)
FROM FUNCTION TO DRUG DISCOVERY: INSIGHTS INTO HYPOTHETICAL PROTEIN RV1979C FROM MYCOBACTERIUM TUBERCULOSIS